The STEP 1 trial randomized 1,961 adults with obesity or overweight, none with diabetes, to once-weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle counseling. The semaglutide group lost an average of 14.9% of body weight; the placebo group lost 2.4%. Nearly one in three treated participants — 32.0% — lost more than 20%.
Semaglutide weight loss results on that scale moved a diabetes medication to the center of weight management: losses that had previously been attainable primarily through bariatric surgery were recorded in a placebo-controlled drug trial. The backdrop makes the numbers matter. Obesity affects more than 650 million adults worldwide by WHO estimates, contributes to diabetes, cardiovascular disease, joint problems, and reduced quality of life, and the traditional toolkit — diet, exercise, and older medications — shows limited long-term success for most people who try it.
This article walks through the published numbers: STEP 1 and STEP 2, a 47-trial meta-analysis, the regain data after stopping, the head-to-head against tirzepatide, and what the trials say about side effects, eligibility, and keeping the results.
From diabetes drug to weight-loss therapy
Semaglutide is a GLP-1 receptor agonist: a synthetic analogue of glucagon-like peptide-1, an incretin hormone the intestine releases in response to food. It entered practice as a type 2 diabetes medication (Ozempic, 2017) and was later brought to market for chronic weight management (Wegovy, 2021) after diabetes trials kept turning up the same side observation — patients lost weight.
Native GLP-1 does four things that matter here: it stimulates insulin secretion only when blood glucose is elevated, suppresses glucagon, slows stomach emptying, and reduces appetite and food intake. In type 2 diabetes trials, GLP-1 receptor agonists improved glycemic control and reduced cardiovascular events — and the consistent weight loss observed along the way prompted dedicated obesity trials in people without diabetes.
The engineering is what makes the drug practical. Native GLP-1 survives in plasma for only a couple of minutes; molecular modifications to semaglutide extend its half-life to roughly 165–168 hours — about a week — which is what allows once-weekly dosing. Earlier drugs in the class required daily (liraglutide) or twice-daily (exenatide) injections, and semaglutide's enhanced stability and receptor affinity have translated into superior results against earlier class members in head-to-head trials.
How semaglutide produces weight loss
The short answer is appetite. Semaglutide activates GLP-1 receptors that are abundant in the brain's appetite-control centers — the hypothalamus and brainstem — which reduces hunger signaling and enhances satiety. It also slows gastric emptying, prolonging fullness after meals, and supports glucose metabolism by pairing glucose-dependent insulin secretion with glucagon suppression.
Older weight-loss drugs generally worked through single pathways — blocking fat absorption, or stimulating metabolism. Semaglutide's effect is broader and, in the Blundell 2017 study of adults with obesity, measurable at the plate: once-weekly semaglutide reduced energy intake, improved control of eating, and shifted food preference — participants reported satisfaction with smaller portions and diminished cravings for high-fat foods.
Patients often describe the effect as a recalibration of the appetite set-point rather than feeling unwell — though the honest caveat is that nausea does contribute for some users, and what mediation analyses support is that the weight loss is largely, not entirely, independent of it. The gastric-emptying delay also attenuates with chronic dosing of long-acting GLP-1 agents, so the early "food sits longer" sensation tends to fade even as weight loss continues.
Two further mechanism notes. First, glucose metabolism improves even in people without diabetes, and weight loss itself improves insulin sensitivity — a virtuous cycle. Second, claims that semaglutide raises resting metabolic rate or fat oxidation remain weakly supported in humans (metabolic rate typically falls as weight falls), so appetite — not a "faster metabolism" — is the mechanism the evidence supports.
Semaglutide weight loss results: STEP 1, STEP 2, and a 47-trial meta-analysis
Three layers of evidence anchor the numbers: a flagship trial in people without diabetes, a parallel trial in people with type 2 diabetes, and a class-wide meta-analysis.
| Study | Population | Duration | Weight result |
|---|---|---|---|
| STEP 1 | 1,961 adults with obesity or overweight, no diabetes | 68 weeks | −14.9% on semaglutide 2.4 mg vs −2.4% placebo |
| STEP 2 | 1,210 adults with overweight or obesity and type 2 diabetes | 68 weeks | −9.64% at 2.4 mg vs −6.99% at 1.0 mg vs −3.42% placebo |
| Wong et al. meta-analysis | 23,244 patients across 47 RCTs, obesity or overweight | varied | −4.57 kg and −2.07 kg/m² BMI vs placebo, GLP-1 class-wide |
In STEP 1, beyond the 14.9% average, 32.0% of semaglutide participants lost more than 20% of body weight versus 1.7% on placebo. The trial's secondary outcomes also showed improvements in blood pressure, triglycerides and other lipids, and inflammatory markers among treated participants.
The meta-analysis published in Diabetes Care pooled 47 randomized controlled trials — 23,244 patients with obesity or overweight, with or without diabetes — and found GLP-1 receptor agonists reduced weight by a mean 4.57 kg (95% CI −5.35 to −3.78), BMI by 2.07 kg/m² (95% CI −2.53 to −1.62), and waist circumference by 4.55 cm versus placebo. The kilogram figure looks modest next to STEP 1's percentage because it averages the whole class, every dose, and shorter trials — it is the conservative floor under the headline results.
In type 2 diabetes, the same drug works measurably less hard on weight. STEP 2 participants on 2.4 mg averaged 9.64% loss over 68 weeks — well ahead of placebo's 3.42% and the lower 1.0 mg dose's 6.99%, and accompanied by a 1.6-percentage-point drop in HbA1c. That gap between diabetic and non-diabetic populations is consistent across the class, and it matters for expectations — as does the fact that some common diabetes medications, such as insulin and sulfonylureas, actively promote weight gain.
Timing, for those watching the scale: appetite effects typically begin within the first few weeks, dose escalation runs over several months (the branded product's schedule steps up over 16 weeks), and in the STEP trials average weight curves plateaued around 60–68 weeks at the maintenance dose.
What happens after stopping: the STEP 1 extension
The weight comes back. In the STEP 1 trial extension, participants who withdrew from semaglutide and lifestyle support regained about two-thirds of their lost weight within one year — from a trough of roughly 15% below baseline down to a net 5.6% below baseline at week 120.
A separate randomized trial published in eClinicalMedicine points the same direction for the class: after an initial 13.1 kg diet-induced loss over 8 weeks in adults with BMI 32–43, participants tended to regain toward their pre-treatment weight in the year after a GLP-1 agonist (liraglutide, in that study) was stopped. Worth noting: some regain reporting has claimed people end up heavier than they started, and neither of these sources supports that — the data show regain approaching, not exceeding, the original loss.
Clinicians draw a consistent conclusion from this: GLP-1 receptor agonists manage obesity, they do not cure it. Obesity behaves as a chronic condition, and the therapy is designed for continued use — the same way stopping a blood-pressure medication lets blood pressure rise again. That framing belongs in the decision before starting, not as a surprise afterward.
Semaglutide vs tirzepatide: the SURMOUNT numbers
Tirzepatide is a dual agonist — it activates both GIP and GLP-1 receptors — and it has beaten single-pathway GLP-1 drugs head-to-head. In SURMOUNT-1, 2,539 adults with obesity and without diabetes averaged 20.9% weight loss at the 15 mg dose over 72 weeks. In the SURMOUNT-5 head-to-head trial (2025), participants on tirzepatide averaged 20.2% loss versus 13.7% on semaglutide. A fuller walk-through of that drug's trial programme is in our tirzepatide clinical trials review.
| Trial | Drug and dose | Population and duration | Average loss |
|---|---|---|---|
| STEP 1 | semaglutide 2.4 mg | 1,961 adults, no diabetes, 68 weeks | −14.9% |
| SURMOUNT-1 | tirzepatide 15 mg | 2,539 adults, no diabetes, 72 weeks | −20.9% |
| SURMOUNT-5 | tirzepatide vs semaglutide | head-to-head, 2025 | −20.2% vs −13.7% |
One correction worth making, because the inflated version circulates widely: tirzepatide's average is sometimes quoted as "20–25%." The trial mean at the highest dose was 20.9%; the 25% figure was a responder threshold — 36.2% of SURMOUNT-1 participants lost at least that much — not an average. Averages and best-case responders are different numbers.
Further out, triple agonists that add glucagon-receptor activity to the GIP/GLP-1 pair are in development; in a phase 2 trial, retatrutide participants averaged 24.2% loss at 48 weeks. It remains investigational and is not something Promise offers; the prescription options Promise does offer in this category are collected under Metabolic Support & Fat Loss.
Benefits beyond the scale: SELECT, liver, and daily life
The largest finding outside weight itself is cardiovascular. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by about 20% in adults with established cardiovascular disease and overweight or obesity who did not have diabetes — a benefit beyond what weight loss alone would predict, echoing earlier cardiovascular outcome trials in type 2 diabetes.
The metabolic picture rounds out the same way. STEP 1's secondary outcomes showed improved blood pressure, lower triglycerides, and reduced inflammatory markers (HDL shifts were small). Among participants with prediabetes, more returned to normal glucose regulation on semaglutide than on placebo — a reduction in diabetes-progression risk, though "reversing diabetes" would overstate the semaglutide evidence.
The liver may benefit too. Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called non-alcoholic fatty liver disease) affects millions and tracks closely with obesity and insulin resistance. In a phase 2 trial in NASH (Newsome and colleagues, 2021), semaglutide resolved steatohepatitis in 59% of treated patients versus 17% on placebo — though that trial did not show significant fibrosis improvement; a later phase 3 programme (ESSENCE, 2024) did report fibrosis improvement. The fair summary: liver fat and inflammation improve; the fibrosis story firmed up only recently.
Finally, quality-of-life measures in the STEP programme — physical functioning, mobility, joint pain (a dedicated knee-osteoarthritis trial, STEP 9, reported pain improvement in 2024), and sleep quality where sleep apnea improves — moved in the right direction alongside the weight.
Side effects, contraindications, and open questions
Gastrointestinal effects dominate. In STEP 1, nausea affected roughly 44% of semaglutide participants and diarrhea about 31%; vomiting, constipation, and abdominal discomfort were also common. Most events were mild to moderate, clustered during dose escalation, and diminished as the body adapted — which is exactly why the dose is titrated slowly. Practical mitigation is unglamorous: smaller portions, skipping very fatty or spicy meals, and steady hydration.
The label's hard stops: semaglutide should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, by anyone with a serious hypersensitivity to it, or during pregnancy. A history of pancreatitis or severe gastrointestinal disease calls for careful evaluation rather than automatic exclusion. Interactions matter in two directions: other glucose-lowering drugs can compound into hypoglycemia, and delayed gastric emptying can change how some oral medications absorb.
On duration: the safety base spans tens of thousands of patient-years across the trial programmes, but controlled long-term data are still measured in years, not decades — around two years in STEP 5 and a mean of 3.3 years in SELECT, with surveillance ongoing. Within that window, the benefits have been sustained and no new safety signal has changed the risk calculus.
Who the label covers — and who tends to benefit
The U.S. prescribing label for weight-management semaglutide covers adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.
Within that population, the profiles that recur in guidelines and clinical experience: people who have genuinely tried diet and exercise without lasting results; people whose weight is already producing complications; and people who describe strong biological hunger drives or poor satiety — the group for whom an appetite-signaling drug addresses the actual problem. Whether any individual is a candidate is a clinical judgment made on their full history, not a checklist.
Keeping the results: food, muscle, and movement
The best trial outcomes came from medication plus structure — nutrition, physical activity, behavioral support, sleep, and stress management together, not the drug alone.
The body-composition data explain why muscle deserves specific attention. In STEP 1's DEXA substudy, roughly 39% of the mass lost was lean tissue. Losing predominantly fat is still the pattern, but that lean fraction is material — which is why adequate protein and resistance training, the two levers shown to preserve lean mass during caloric restriction, belong in any semaglutide plan.
Exercise also pays independently of the scale — cardiovascular conditioning, bone density, mood, and metabolic health all improve whether or not weight moves. And it changes what happens after treatment: in the eClinicalMedicine trial, people who had combined structured exercise with the GLP-1 agonist held a 5.1 kg weight advantage and a 2.3-percentage-point body-fat advantage over drug-alone participants at week 104 — a full year after all treatment stopped.
Obesity also has emotional and behavioral dimensions that no injection reaches. Cognitive behavioral therapy, stress management, and support groups are evidence-supported complements, not afterthoughts.
Where semaglutide fits — and who decides
The evidence supports a clear, bounded claim: in large randomized trials, once-weekly semaglutide produced average weight losses around 15% in adults with obesity and around 10% in adults who also had type 2 diabetes, with cardiovascular, metabolic, and liver benefits accumulating alongside — and with real limits attached. The weight largely returns when treatment stops, gastrointestinal side effects are common early, long-term data are still measured in years, and every figure above is a population average from trials that paired the drug with lifestyle change.
Semaglutide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. It is available by prescription only — a licensed provider in Promise's prescriber network reviews every request, not everyone qualifies, and a provider may decline where the medical picture doesn't support treatment. That review is where trial averages meet your actual history, and it is the right place for the decision to be made.
This article is for general education, not medical advice. Talk with a licensed healthcare provider about your own health before starting, stopping, or changing any medication.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971–984. https://pubmed.ncbi.nlm.nih.gov/33667417/
- Wong HJ, Sim B, Teo YH, et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care. 2025;48(2):292–300. https://pubmed.ncbi.nlm.nih.gov/39841962/
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
- Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine. 2024;69:102475. https://pubmed.ncbi.nlm.nih.gov/38544798/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. https://pubmed.ncbi.nlm.nih.gov/28266779/